CD20 × CD3 bispecific antibodies bind to both CD20 on malignant B cells and CD3 on T cells, bringing them into close proximity, which triggers T cell-mediated killing of the targeted B cells.

The histological diagnosis was lymphocytic hypophysitis. Immunostains were positive for CD3 and CD20. Immunostains for acid-fast bacilli, PLAP and OCT3/4 were negative. The patient remains ...

The first-in-class drug – which targets CD20 and CD3 – is being assessed by the regulator for relapsed or refractory FL, the most common slow-growing form of non-Hodgkin lymphoma (NHL), after ...

Roche has secured approval from the European Commission (EC) for Columvi (glofitamab) plus gemcitabine and oxaliplatin (GemOx ...

Xencor's stock drops 65%, hitting all-time lows. Focus shifts to autoimmune research, but no near-term catalysts. Read why ...

Investment company RTW Investments has launched a new biotech company called Prolium Bioscience, to advance the development ...

Background: Pulmonary mucosa-associated lymphoid tissue (MALT) lymphoma is a rare, indolent subtype of non-Hodgkin lymphoma ...

The firm’s product pipeline includes IGM-2323, which is a CD20 x CD3 bispecific IgM antibody designed to treat patients with B cell Non-Hodgkin's lymphoma and other B cell malignancies ...

Lunsumio is a CD20/CD3 T cell-engaging bispecific antibody designed to target CD20 on B cells and CD3 on T cells. Lunsumio is expected to activate the immune system through cytotoxic T cells and have ...

Because of the often nonspecific nature of MCL, diagnostic efforts need to be better streamlined to reduce the risk of misdiagnosis.